Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 255-263

  Sarma, Satyam ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiac metabolism; Fatty acid metabolism; Fibrates; Heart failure; PPAR; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [2 (2 NAPHTHYLMETHYL) 5 BENZOXAZOLYLMETHYL] 2,4 THIAZOLIDINEDIONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FARGLITAZAR; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PD 168; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; EDEMA; FATTY ACID METABOLISM; GENE OVEREXPRESSION; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE METABOLISM; HOSPITAL COST; HUMAN; ISCHEMIC HEART DISEASE; LIPOTOXICITY; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 84861746412     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020255     Document Type: Review

References (82)

1. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347(6294), 645-650.
2. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68(5), 879-887.
3. McEwan, I.J. Nuclear receptors: one big family. Methods Mol. Biol., 2009, 505, 3-18.
4. Vidal-Puig, A.J.; Considine, R.V.; Jimenez-Liñan, M.; Werman, A.; Pories, W.J.; Caro J.F.; Flier J.S. Peroxisome proliferatoractivated receptor gene expression in human tissues. Effects of obesity.; weight loss.; and regulation by insulin and glucocorticoids. J. Clin. Invest., 1997, 99(10), 2416-2422.
5. Kliewer, S.A.; Forman, B.M.; Blumberg, B.; Ong, E.S.; Borgmeyer, U.; Mangelsdorf, D.J.; Umesono, K.; Evans, R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 1994, 91(15), 7355-7359.
6. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
7. Forman, B.M.; Tontonoz, P.; Chen, J.; Brun, R.P.; Spiegelman B.M.; Evans R.M. 15-Deoxy-delta 12.; 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 1995, 83(5), 803-812.
8. Ventura-Clapier, R.; Garnier, A.; Veksler, V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc. Res., 2008, 79(2), 208-217.
9. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.M.; Heyman, R.A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 1996, 15(19), 5336-5348.
10. Bishop-Bailey, D.; Bystrom, J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol. Ther., 2009, 124(2), 141-150.
11. Taegtmeyer, H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Probl. Cardiol., 1994, 19(2), 59-113.
12. Ashrafian, H.; Frenneaux, M.P.; Opie, L.H. Metabolic mechanisms in heart failure. Circulation, 2007, 116(4), 434-448.
13. Hertz, R.; Bar-Tana, J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol. Lett., 1998, 102-103, 85-90.
14. Finck, B.N.; Kelly, D.P. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J. Mol. Cell. Cardiol., 2002, 34(10), 1249-1257.
15. Campbell, F.M.; Kozak, R.; Wagner, A.; Altarejos, J.Y.; Dyck, J.R.; Belke, D.D.; Severson, D.L.; Kelly, D.P.; Lopaschuk, G.D. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem., 2002, 277(6), 4098-4103.
16. Gilde, A.J.; van der Lee, K.A.; Willemsen, P.H.; Chinetti, G.; van der Leij, F.R.; van der Vusse, G.J.; Staels, B.; van Bilsen, M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta.; but not PPARgamma.; modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res., 2003, 92(5), 518-524.
17. Duan, S.Z.; Ivashchenko, C.Y.; Russell, M.W.; Milstone, D.S.; Mortensen, R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Cir. Res., 2005, 97(4), 372-379.
18. Cheng, L.; Ding, G.; Qin, Q.; Huang, Y.; Lewis, W.; He, N.; Evans, R.M.; Schneider, M.D.; Brako, F.A.; Xiao, Y.; Chen, Y.E.; Yang, Q. Cardiomyocyte-restricted peroxisome proliferatoractivated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med., 2004, 10(11), 1245-1250.
19. Finck, B.N.; Lehman, J.J.; Leone, T.C.; Welch, M.J.; Bennett, M.J.; Kovacs, A.; Han, X.; Gross, R.W.; Kozak, R.; Lopaschuk, G.D.; Kelly, D.P. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest., 2002, 109(1), 121-130.
20. Son, N.H.; Park, T.S.; Yamashita, H.; Yokoyama, M.; Huggins, L.A.; Okajima, K.; Homma, S.; Szabolcs, M.J.; Huang, L.S.; Goldberg, I.J. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J. Clin. Invest., 2007, 117(10), 2791-2801.
21. Herrero, P.; Peterson, L.R.; McGill, J.B.; Matthew, S.; Lesniak, D.; Dence, C.; Gropler, R.J. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J. Am. Coll. Cardiol., 2006, 47(3), 598-604.
22. Zhou, Y.T.; Grayburn, P.; Karim, A.; Shimabukuro, M.; Higa, M.; Baetens, D.; Orci, L.; Unger, R.H. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA, 2000, 97(4), 1784-1789.
23. Park, T.S.; Hu, Y.; Noh, H.L.; Drosatos, K.; Okajima, K.; Buchanan, J.; Tuinei, J.; Homma, S.; Jiang, X.C.; Abel, E.D.; Goldberg, I.J. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res., 2008, 49(10), 2101-2112.
24. Son, N.H.; Yu, S.; Tuinei, J.; Arai, K.; Hamai, H.; Homma, S.; Shulman, G.I.; Abel, E.D.; Goldberg, I.J. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J. Clin. Invest., 2010, 120(10), 3443-3454.
25. Duncan, J.G.; Bharadwaj, K.G.; Fong, J.L.; Mitra, R.; Sambandam, N.; Courtois, M.R.; Lavine, K.J.; Goldberg, I.J.; Kelly, D.P. Rescue of cardiomyopathy in peroxisome proliferator-activated receptoralpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation, 2010, 121(3), 426-435.
26. Yang, J.; Sambandam, N.; Han, X.; Gross, R.W.; Courtois, M.; Kovacs, A.; Febbraio, M.; Finck, B.N.; Kelly, D.P. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ. Res., 2007, 100(8), 1208-1217.
27. Marfella, R.; Portoghese, M.; Ferraraccio, F.; Siniscalchi, M.; Babieri, M.; Di Filippo, C.; D'Amico, M.; Rossi, F.; Paolisso, G. Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function. Heart, 2009, 95(12), 1020-1022.
28. Marfella, R.; Portoghese, M.; Ferraraccio, F.; Siniscalchi, M.; Babieri, M.; Di Filippo, C.; D'Amico, M.; Rossi, F.; Paolisso, G. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J. Lipid Res., 2009, 50(11), 2314-2323.
29. Karbowska, J.; Kochan, Z.; Smolenski, R.T. Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cell Mol. Biol. Lett., 2003, 8(1), 49-53.
30. Dewald, O.; Sharma, S.; Adrogue, J.; Salazar, R.; Duerr, G.D.; Crapo, J.D.; Entman, M.L.; Taegtmeyer, H. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation, 2005, 112(3), 407-415.
31. Goikoetxea, M.J.; Beaumont, J.; González, A.; López, B.; Querejeta, R.; Larman, M.; Díez, J. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovasc. Res., 2006, 69(4), 899-907.
32. Morgan, E.E.; Chandler, M.P.; Young, M.E.; McElfresh, T.A.; Kung, T.A.; Rennison, J.H.; Tserng, K.Y.; Hoit, B.D.; Stanley, W.C. Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure. Eur. J. Heart Fail., 2006, 8(7), 687-693.
33. Barger, P.M.; Brandt, J.M.; Leone, T.C.; Weinheimer, C.J.; Kelly, D.P. Deactivation of peroxisome proliferator-activated receptoralpha during cardiac hypertrophic growth. J. Clin. Invest., 2000, 105(12), 1723-1730.
34. Huss, J.M.; Levy, F.H.; Kelly, D.P. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J. Biol. Chem., 2001, 276(29), 27605-27612.
35. Huss, J.M.; Kelly, D.P. Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Invest., 2005, 115(3), 547-555.
36. Burkart, E.M.; Sambandam, N.; Han, X.; Gross, R.W.; Courtois, M.; Gierasch, C.M.; Shoghi, K.; Welch, M.J.; Kelly, D.P. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest., 2007, 117(12), 3930-3939.
37. Liu, J.; Wang, P.; Luo, J.; Huang, Y.; He, L.; Yang, H.; Li, Q.; Wu, S.; Zhelyabovska, O.; Yang, Q. Peroxisome proliferator-activated receptor beta/delta activation in adult hearts facilitates mitochondrial function and cardiac performance under pressureoverload condition. Hypertension, 2011, 57(2), 223-230.
38. Martin, G.; Schoonjans, K.; Staels, B.; Auwerx, J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis, 1998, (Suppl. 137), S75-80.
39. Shintani, M.; Nishimura, H.; Yonemitsu, S.; Ogawa, Y.; Hayashi, T.; Hosoda, K.; Inoue, G.; Nakao, K. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes, 2001, 50(10), 2296-2300.
40. Pasceri, V.; Wu, H.D.; Willerson, J.T.; Yeh, E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation, 2000, 101(3), 235-238.
41. De Silva, D.S.; Wilson, R.M.; Hutchinson, C.; Ip, P.C.; Garcia, A.G.; Lancel, S.; Ito, M.; Pimentel, D.R.; Sam, F. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(6), H1983-1993.
42. Wu, J.S.; Lin, T.N.; Wu, K.K. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J. Cell. Physiol., 2009, 220(1), 58-71.
43. Alvarez-Guardia, D.; Palomer, X.; Coll, T.; Serrano, L.; Rodríguez-Calvo, R.; Davidson, M.M.; Merlos, M.; El Kochairi, I.; Michalik, L.; Wahli, W.; Vázquez-Carrera, M. PPARbeta/delta activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta, 2011, 1811(2), 59-67.
44. Purcell, N.H.; Tang, G.; Yu, C.; Mercurio, F.; DiDonato, J.A.; Lin, A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. USA, 2001, 98(12), 6668-6673.
45. Rival, Y.; Benéteau, N.; Taillandier, T.; Pezet, M.; Dupont-Passelaigue, E.; Patoiseau, J.F.; Junquéro, D.; Colpaert, F.C.; Delhon, A. PPARalpha and PPARdelta activators inhibit cytokineinduced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol., 2002, 435(2-3), 143-151.
46. Liang, Y.J.; Liu, Y.C.; Chen, C.Y.; Lai, L.P.; Shyu, K.G.; Juang, S.J.; Wang, B.W.; Leu, J.G. Comparison of PPARdelta and PPARgamma in inhibiting the pro-inflammatory effects of Creactive protein in endothelial cells. Int. J. Cardiol., 2010, 143(3), 361-367.
47. Lee, C.H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W.A.; Evans, R.M.; Curtiss, L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science, 2003, 302(5644), 453-457.
48. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H.M.; Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 1990, 323(4), 236-241.
49. Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; Krum, H.; Liu, P.; Nieminen, M.; Tavazzi, L.; van Veldhuisen, D.J.; Waldenstrom, A.; Warren, M.; Westheim, A.; Zannad, F.; Fleming, T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 2004, 109(13), 1594-1602.
50. Curtis, L.H.; Whellan, D.J.; Hammill, B.G.; Hernandez, A.F.; Anstrom, K.J.; Shea, A.M.; Schulman, K.A. Incidence and prevalence of heart failure in elderly persons.; 1994-2003. Arch. Intern. Med., 2008, 168(4), 418-424.
51. Rosamond, W.; Flegal, K.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.M.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd-Jones, D.; McDermott, M.; Meigs, J.; Moy, C.; Nichol, G.; O'Donnell, C.; Roger, V.; Sorlie, P.; Steinberger, J.; Thom, T.; Wilson, M.; Hong, Y.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117(4), e25-146.
52. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson, T.B.; Ford, E.; Furie, K.; Gillespie, C.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, P.M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.M.; Meigs, J.; Mozaffarian, D.; Mussolino, M.; Nichol, G.; Roger, V.L.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.D.; Wylie-Rosett, J.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation, 2010, 121(7), 948-954.
53. Herrmann, G.; Dechard, D.G. The chemical nature of heart failure. Ann. Intern. Med., 1939, 12, 1233-1244.
54. Neubauer, S.; Horn, M.; Cramer, M.; Harre, K.; Newell, J.B.; Peters, W.; Pabst, T.; Ertl, G.; Hahn, D.; Ingwall, J.S.; Kochsiek, K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation, 1997, 96(7), 2190-2196.
55. Depre, C.; Vanoverschelde, J.L.; Gerber, B.; Borgers, M.; Melin, J.A.; Dion, R. Correlation of functional recovery with myocardial blood flow.; glucose uptake.; and morphologic features in patients with chronic left ventricular ischemic dysfunction undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 1997, 113(2), 371-378.
56. Nikolaidis, L.A.; Sturzu, A.; Stolarski, C.; Elahi, D.; Shen, Y.T.; Shannon, R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc. Res., 2004, 61(2), 297-306.
57. Nissen, S.E.; Wolski, K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch. Intern. Med., 2010, 170(14), 1191-1201.
58. Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; Young, L.H.; Kahn, R.; American Heart Association; American Diabetes Association. Thiazolidinedione use.; fluid retention.; and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7.; 2003. Circulation, 2003, 108(23), 2941-2948.
59. Zhang, H.; Zhang, A.; Kohan, D.E.; Nelson, R.D.; Gonzalez, F.J.; Yang, T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedioneinduced fluid retention. Proc. Natl. Acad. Sci. USA, 2005, 102(26), 9406-9411.
60. Dargie, H.J.; Hildebrandt, P.R.; Riegger, G.A.; McMurray, J.J.; McMorn, S.O.; Roberts, J.N.; Zambanini, A.; Wilding, J.P. A randomized.; placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol., 2007, 49(16), 1696-1704.
61. Aguilar, D.; Bozkurt, B.; Pritchett, A.; Petersen, N.J.; Deswal, A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J. Am. Coll. Cardiol., 2007, 50(1), 32-36.
62. Francis, G.A.; Fayard, E.; Picard, F.; Auwerx, J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol., 2003, 65, 261-311.
63. Frick, M.H.; Elo, O.; Haapa, K.; Heinonen, O.P.; Heinsalmi. P.; Helo, P.; Huttunen, J.K.; Kaitaniemi, P.; Koskinen, P.; Manninen, V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment.; changes in risk factors.; and incidence of coronary heart disease. N. Engl. J. Med., 1987, 317(20), 1237-1245.
64. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G.; Wilt, T.J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341(6), 410-418.
65. Wysocki, J.; Belowski, D.; Kalina, M.; Kochanski, L.; Okopien, B.; Kalina, Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int. J. Clin. Pharmacol. Ther., 2004, 42(4), 212-217.
66. Sarma, S.; Ardehali, H.; Gheorghiade, M. Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail. Rev., 2010 [Epub ahead of print]
67. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356(24), 2457-2471.
68. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet, 1984, 2(8403), 600-604.
69. Saha, S.A.; Kizhakepunnur, L.G.; Bahekar, A.; Arora, R.R. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J., 2007, 154(5), 943-953.
70. Yang, T.; Michele, D.E.; Park, J.; Smart, A.M.; Lin, Z.; Brosius, F. C 3rd.; Schnermann, J.B.; Briggs, J.P. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol., 1999, 277(6 Pt. 2), F966-973.
71. Chen, L.; Yang, B.; McNulty, J.A.; Clifton, L.G.; Binz, J.G.; Grimes, A.M.; Strum, J.C.; Harrington, W.W.; Chen, Z.; Balon, T.W.; Stimpson, S.A.; Brown, K.K. GI262570.; a peroxisome proliferator-activated receptor {gamma} agonist.; changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther., 2005, 312(2), 718-725.
72. Weiss, C.S.; Hagenmüller, M.; Pichler, M.; Münz, S.; Ochs, M.; Buss, S.J.; Bekeredjian, R.; Katus, H.A.; Hardt, S.E. Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. Naunyn, Schmiedebergs Arch. Pharmacol., 2010, 381(4), 285-295.
73. Kapoor, A.; Collino, M.; Castiglia, S.; Fantozzi, R.; Thiemermann, C. Activation of peroxisome proliferator-activated receptorbeta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock, 2010, 34(2), 117-124.
74. Blasi, E.R.; Heyen, J.; Hemkens, M.; McHarg, A.; Ecelbarger, C.M.; Tiwari, S. Effects of Chronic PPAR-Agonist Treatment on Cardiac Structure and Function.; Blood Pressure.; and Kidney in Healthy Sprague-Dawley Rats. PPAR Res., 2009, 237865.
75. Geng, D.F.; Wu, W.; Jin, D.M.; Wang, J.F.; Wu, Y.M. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int. J. Cardiol., 2006, 113(1), 86-91.
76. Vikramadithyan, R.K.; Hirata, K.; Yagyu, H.; Hu, Y.; Augustus, A.; Homma, S.; Goldberg, I.J. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J. Pharmacol. Exp. Ther., 2005, 313(2), 586-593.
77. Golfman, L.S.; Wilson, C.R.; Sharma, S.; Burgmaier, M.; Young, M.E.; Guthrie, P.H.; Van Arsdall, M.; Adrogue, J.V.; Brown, K.K.; Taegtmeyer, H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am. J. Physiol. Endocrinol. Metab., 2005, 289(2), E328-336.
78. Arakawa, K.; Ishihara, T.; Aoto, M.; Inamasu, M.; Kitamura, K.; Saito, A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin. Exp. Pharmacol. Physiol., 2004, 31(1-2), 8-13.
79. Xu, Y.; Lu, L.; Greyson, C.; Lee, J.; Gen, M.; Kinugawa, K.; Long, C.S.; Schwartz, G.G. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes, 2003, 52(5), 1187-1194.
80. Ito, H.; Nakano, A.; Kinoshita, M.; Matsumori, A. Pioglitazone.; a peroxisome proliferator-activated receptor-gamma agonist.; attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest., 2003, 83(12), 1715-1721.
81. Asakawa, M.; Takano, H.; Nagai, T.; Uozumi, H.; Hasegawa, H.; Kubota, N.; Saito, T.; Masuda, Y.; Kadowaki, T.; Komuro, I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation, 2002, 105(10), 1240-1246.
82. Shiomi, T.; Tsutsui, H.; Hayashidani, S.; Suematsu, N.; Ikeuchi, M.; Wen, J.; Ishibashi, M.; Kubota, T.; Egashira, K.; Takeshita, A. Pioglitazone.; a peroxisome proliferator-activated receptor-gamma agonist.; attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002, 106(24), 3126-3132.